Lilly enlists new tech partner to improve outcomes in diabetes by Beth Snyder Bulik Monday, February 12, 2018 Eli Lilly and Livongo team up to tap real-world data to help diabetes patients adopt healthier habits and save money—and boost treatment results, too.
Lilly builds $23B sales forecast on diabetes, cancer launches by Eric Sagonowsky Wednesday, December 13, 2017 Eli Lilly is aiming for $23 billion in 2018 revenue, but it'll have to contend with a tough environment in diabetes and one hefty patent expiration.
Sanofi sues Mylan for Lantus patent infringement by Eric Sagonowsky Wednesday, October 25, 2017 Already under fire from one Lantus challenger, Sanofi is suing Mylan in an effort to hold off that company's version of its top-selling drug.
Merck scores FDA nod for Lantus copy Lusduna by Tracy Staton Thursday, July 20, 2017 Merck & Co. nabbed tentative FDA approval for its Lantus copy, Lusduna, which would be the second follow-on challenger to the Sanofi blockbuster.
With new FDA app, Novo aims for Tresiba edge by Tracy Staton Tuesday, May 30, 2017 Novo Nordisk just took another step toward a potential kick-start for its newest basal insulin, Tresiba.
Diabetes boost can't save Lilly from Q4 miss by Arlene Weintraub Tuesday, January 31, 2017 Eli Lilly sales beat estimates, thanks to higher-than-expected diabetes revenue and aging ED drug Cialis. But earnings fell short on soaring expenses.
Lilly's Lantus biosim arrives to poach already hard-hit Sanofi sales by Carly Helfand Thursday, December 15, 2016 Eli Lilly and Boehringer Ingelheim's Lantus biosim Basaglar, scheduled to launch Thursday, brings Sanofi some unwanted competition in the basal insulin market.
